Licensing opportunity
Drug delivery specialist Atacama Labs is making its new drug delivery technology available for licensing worldwide through commercial partner Bridgehead International.
The technology pneumatic dry granulation (PDG) applies to the formulation of solid oral dosage forms, replacing existing development and manufacturing methods to create significantly faster development times and improved formulations.
PDG’s capabilities have been demonstrated in a variety of evaluation studies with leading pharmaceutical companies. “In a single day’s work with PDG, we successfully created formulations that clearly met the target criteria of our clients, whose own efforts over several months using traditional methods had been less successful,” said Petri Rahja, Director of Delivery, Atacama Labs.
“We are delighted to partner with Atacama Labs and are convinced that our mix of commercial, technical and IP experience will help them maximise the uptake of this product throughout the pharmaceutical industry”, said Fiona Paton of Bridgehead.
PDG enables flexible modification of drug load, disintegration time and tablet hardness. It is suitable for a wide range of compounds with different physicochemical properties, including heat labile and moisture sensitive drugs. Very high drug loading can be achieved and stability and taste-masking is excellent. PDG can be used in conjunction with other technologies, such as sustained release, fast release and coating.
Atacama Labs is a privately owned company founded in 2005, and located in Espoo, Finland.
Bridgehead International provides a range of specialist consultancy services to the pharmaceutical and biotechnology sectors, including technical and commercial due diligence and pricing, reimbursement and market access strategy.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
